| CPC C07H 19/056 (2013.01) | 15 Claims |
|
1. A compound of Formula (I)
 wherein
R1 represents
an amide group of the structure:
 wherein
RN11 represents
—C1-6-alkyl;
—CH2—CH2—O—C1-3-alkyl;
—CH2—C1-3-fluoroalkyl;
—C0-2-alkylene-C3-6-cycloalkyl, wherein said C3-6-cycloalkyl is unsubstituted or mono- or di-substituted with fluoro or methyl;
—C0-2-alkylene-C4-6-cycloalkyl wherein said C4-6-cycloalkyl contains one oxygen ring atom;
—CH2—CH2—NRN21RN22, wherein RN21 and RN22 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl selected from azetidine-1-yl, pyrrolidine-1-yl, piperidine-1-yl, and morpholin-4-yl; or
—C1-2-alkylene-R11, wherein R11 represents phenyl or 5- or 6-membered heteroaryl wherein said phenyl or 5- or 6-membered heteroaryl independently is unsubstituted or mono-substituted with methyl;
phenyl or 5- or 6-membered heteroaryl wherein said phenyl or 5- or 6-membered heteroaryl independently is unsubstituted or mono-substituted with methyl; or
 and RN12 represents hydrogen or C1-2-alkyl;
or RN11 and RN12 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl selected from azetidine-1-yl, pyrrolidine-1-yl, and piperidine-1-yl, wherein said 4- to 6-membered heterocyclyl independently is unsubstituted, mono-, or di-substituted, wherein the substituents independently are methyl or fluoro;
or RN11 and RN12 together with the nitrogen atom to which they are attached form morpholin-4-yl;
or RN11 and RN12 together with the nitrogen atom to which they are attached to form a partially aromatic bicyclic ring consisting of a pyrrolidine-1-yl or a piperidine-1-yl, wherein said pyrrolidine or piperidine is fused to a phenyl ring;
Ar1 represents
aryl which is mono-, di-, tri-, tetra-, or penta-substituted, wherein the substituents are independently selected from halogen, methyl, cyano, and methoxy; or
5- or 6-membered heteroaryl, wherein said 5- or 6-membered heteroaryl independently is unsubstituted, mono- or di-substituted, wherein the substituents are independently selected from halogen, methyl, cyano, and methoxy;
R2a represents hydrogen; and R2b represents
—C2-4-alkyl,
—C0-1-alkylene-Ar2b, wherein Ar2b represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is unsubstituted, mono- or di-substituted with methyl;
or R2a and R2b both represent hydrogen, methyl, ethyl, or n-propyl;
or R2a and R2b together with the carbon atom to which they are attached form a 3- to 6-membered ring selected from
C3-6-cycloalkylene, wherein said C3-6-cycloalkylene independently is unsubstituted, mono-, or di-substituted, wherein the substituents independently are methyl or fluoro;
tetrahydro-2H-pyran-4,4-diyl, which is unsubstituted, di-, or tetra-substituted with methyl; or
piperidine-4,4-diyl, pyrrolidine-3,3-diyl, or azetidine-3,3-diyl wherein the nitrogen of said piperidine, pyrrolidine or azetidine independently is unsubstituted, or substituted with —C1-3-alkyl, —C0-2-alkylene-C3-6-cycloalkyl, or -L-RN2 wherein
-L- represents —CO—, —SO2—, *—CO—NH—, *—CO—O—, or *—SO2—NH—, and
RN2 represents —C1-3-alkyl or —C0-2-alkylene-C3-6-cycloalkyl;
wherein in the above groups the asterisks indicate the bond which is connected to the rest of the molecule; or
R2a and R2b together with the carbon atom to which they are attached form a spiro-bicyclic ring system of the structure (S2AB)
 wherein ring (A) represents a 3- to 6-membered non-aromatic carbocyclic ring, wherein said 3- to 6-membered non-aromatic carbocyclic ring optionally contains one ring oxygen atom and wherein said 3- to 6-membered non-aromatic carbocyclic ring is unsubstituted or di-substituted with fluoro; and
R3 represents hydroxy or C1-3-alkoxy;
or a pharmaceutically acceptable salt thereof.
|